ZYX

Across TCGA pan-cancer cohorts, ZYX Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZYX data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ZYX Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZYX expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BRCA, LIHC, and BLCA are the cancer types where ZYX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.027	0.907	<.001	36	view →
LIHC	OS	Median	All	0.033	0.784	<.001	24	view →
BLCA	DFS	Median	All	1.000	0.326	.026	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.407	0.786	.007	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZYX–BRCA (OS)

Open the BRCA breakdown →